Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Adicet Bio, Inc. (ACET : NSDQ)

• Company Description    Adicet Bio Inc. is a biotechnology company. It engages in discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet Bio Inc., formerly known as RESTORBIO INC, is based in Calif. Number of Employees: 152

• Price / Volume Information    Yesterday's Closing Price: $8.42 Daily Weekly Monthly 20 Day Moving Average: 185,262 shares Shares Outstanding: 9.58 (millions) Market Capitalization: $80.65 (millions) Beta: 1.60 52 Week High: $17.76 52 Week Low: $7.15 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.18% -5.02% 12 Week -42.44% -43.36% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 131 DARTMOUTH STREET 3RD FLOOR - BOSTON,MA 02116 USA ph: 650-503-9095 fax: - abowdidge@adicetbio.com http://www.adicetbio.com

• General Corporate Information    Officers Chen Schor - President; Chief Executive Officer and Director Nick Harvey - Chief Financial Officer Jeffrey Chodakewitz - Director Steve Dubin - Director Carl L. Gordon - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 007002207 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/05/26 Share - Related Items Shares Outstanding: 9.58 Most Recent Split Date: 12.00 (0.06:1) Beta: 1.60 Market Capitalization: $80.65 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-2.80 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-11.60 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.40 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 14.71% vs. Previous Quarter: 14.71% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -77.90 06/30/25 - -68.48 ROA 12/31/25 - - 09/30/25 - -64.35 06/30/25 - -57.84 Current Ratio 12/31/25 - - 09/30/25 - 5.62 06/30/25 - 7.48 Quick Ratio 12/31/25 - - 09/30/25 - 5.62 06/30/25 - 7.48 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - 20.98 06/30/25 - 25.80 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.01 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.57 06/30/25 - 0.00

Powered by Zacks Investment Research ©